MBC BioLabs
953 Indiana St., San Francisco, CA 94107
OUR DISCOVERY
targeting chromatin networks
There is a necessity for new types of treatments in chromatin driven diseases like pediatric diffuse midline glioma (DMG).
TippingPoint has found a way to recapitulate the disease driving chromatin interactions in a test tube and uniquely target these aberrant interactions in disease.
OUR MISSION & VISION
TippingPoint Biosciences' mission is to treat diseases caused by dysfunctional genome chromatin packaging that are difficult to target using conventional approaches.
Chromatin structure dictates cell function and identity.
OUR SOLUTION
Team & advisory
Dr. Laura Hsieh is a former UCSF and American Cancer Society postdoctoral fellow in Dr.Narlikar’s lab and original inventor of the platform
Dr. Geeta Narlikar is Professor and Chair at the Biochemistry and Biophysics Department in UCSF and member of the US National Academy of Sci
Dr. Muryam Gourdet obtained her PhD from the TETRAD program at UCSF.
Dr. Anna Ye obtained her PhD from UC Davis, did a postdoc at UC Berkeley in Cell Biology and was a senior scientist at Hexagon Bio and Brigh
Dr. Donna Huryn is a Chemistry Professor at University of Pennsylvania, American Chemical Society Fellow and former medicinal chemist at Hof
Dr. Li was most recently the Senior Vice President and Head or Translational Medicine at RazyeBio, the former Senior Vice President of Trans
Parker Grosjean is a UCSF graduate student with an expertise in AI-based imaging and chemoinformatics.
Dr. David Raleigh is an Assistant Professor of Radiation Oncology at UCSF and Brain Tumor Center Preclinical Therapeutics Core Director.
Dr. Michelle Monje is a HHMI Professor of Neurology and Neuro-Oncologist at Stanford University and MacArthur Fellow.
Dr. Mike Keiser was a Professor of Pharmaceutical Chemistry at UCSF and co-founder of a stealth start-up. His expertise is in developing ML
Dr. Paula Ragan is the, Founder, CEO & President of X4 Pharmaceuticals. She was also a former CBO consultant at Lysosomal Therapeutics a
Dr. Ralph Lin is currently at Avidity Biosciences. He has held multiple leadership roles at various biotech companies including Arena Pharma
Dr. Danica Fujimori is a Professor in the Department of Pharmacology at UCSF and co-founder of a stealth start-up.
Dr. Laura Hsieh is a former UCSF and American Cancer Society postdoctoral fellow in Dr.Narlikar’s lab and original inventor of the platform
Dr. Geeta Narlikar is Professor and Chair at the Biochemistry and Biophysics Department in UCSF and member of the US National Academy of Sci
Dr. Muryam Gourdet obtained her PhD from the TETRAD program at UCSF.
Dr. Donna Huryn is a Chemistry Professor at University of Pennsylvania, American Chemical Society Fellow and former medicinal chemist at Hof
Dr. Li was most recently the Senior Vice President and Head or Translational Medicine at RazyeBio, the former Senior Vice President of Trans
Parker Grosjean is a UCSF graduate student with an expertise in AI-based imaging and chemoinformatics.
Dr. David Raleigh is an Assistant Professor of Radiation Oncology at UCSF and Brain Tumor Center Preclinical Therapeutics Core Director.
Dr. Michelle Monje is a HHMI Professor of Neurology and Neuro-Oncologist at Stanford University and MacArthur Fellow.
Dr. Mike Keiser was a Professor of Pharmaceutical Chemistry at UCSF and co-founder of a stealth start-up. His expertise is in developing ML
Dr. Paula Ragan is the, Founder, CEO & President of X4 Pharmaceuticals. She was also a former CBO consultant at Lysosomal Therapeutics a
Dr. Ralph Lin is currently at Avidity Biosciences. He has held multiple leadership roles at various biotech companies including Arena Pharma
Dr. Danica Fujimori is a Professor in the Department of Pharmacology at UCSF and co-founder of a stealth start-up.
.svg)
Open positions
Check back in a while or write to us.
NEWS & PRESS RELEASES
Stay informed to empower yourself with the latest knowledge and insights.
December 12, 2023
Astellas received more than 25 applications for the prize. After careful consideration and a competitive pitch process, both companies were chosen for strength of the innovation in their approach, the therapeutic potential of their research and expandability of their technological platforms.
October 17, 2023
More than 30 startups — including 18 from the Bay Area — pitched to investors at an event leading up to the Biotechnology Innovation Organization's Investor Forum on Tuesday and Wednesday.
September 15, 2023
We talked with the founder of TippingPoint Biosciences — Laura Hsieh, CEO — in the basement of IndieBio last week after her company had just been voted “Killer of the Week” by her peers in Batch 14. Each week at IndieBio, the companies in our batch compete based on their top accomplishments just in the previous week as they learn to move at venture speed. Top companies are nominated by the IndieBio SF team, but the winner is ultimately chosen by a voting of their peers within the batch.
January 7, 2023
A wide number of cancers exhibit misregulated genome packaging at the chromatin level. If chromatin that should be tightly condensed, becomes loosely packed (or vice-versa), the normal brakes on cell growth aren’t operant, leading to uncontrolled cell growth. Being able to regulate and control the chromatin state has been a high-value target for oncology.
November 9, 2023
Within each of the trillions of cells in our bodies, more than six feet of DNA is carefully packaged, encoding instructions for the biological processes we need to live. The secret to that precise packaging, which allows so much DNA to compress into the tiny space of a cell’s nucleus, lies in the power of the nucleosome.
December 12, 2023
Astellas received more than 25 applications for the prize. After careful consideration and a competitive pitch process, both companies were chosen for strength of the innovation in their approach, the therapeutic potential of their research and expandability of their technological platforms.
October 17, 2023
More than 30 startups — including 18 from the Bay Area — pitched to investors at an event leading up to the Biotechnology Innovation Organization's Investor Forum on Tuesday and Wednesday.
September 15, 2023
We talked with the founder of TippingPoint Biosciences — Laura Hsieh, CEO — in the basement of IndieBio last week after her company had just been voted “Killer of the Week” by her peers in Batch 14. Each week at IndieBio, the companies in our batch compete based on their top accomplishments just in the previous week as they learn to move at venture speed. Top companies are nominated by the IndieBio SF team, but the winner is ultimately chosen by a voting of their peers within the batch.
January 7, 2023
A wide number of cancers exhibit misregulated genome packaging at the chromatin level. If chromatin that should be tightly condensed, becomes loosely packed (or vice-versa), the normal brakes on cell growth aren’t operant, leading to uncontrolled cell growth. Being able to regulate and control the chromatin state has been a high-value target for oncology.
November 9, 2023
Within each of the trillions of cells in our bodies, more than six feet of DNA is carefully packaged, encoding instructions for the biological processes we need to live. The secret to that precise packaging, which allows so much DNA to compress into the tiny space of a cell’s nucleus, lies in the power of the nucleosome.
If you are interested in learning more about our revolutionary technology, please contact us at:
hello@tippingpointbiosciences.com
